
INTELLIPHARMACEUTICS INTERNA (IPCI.CA) Fundamental Analysis & Valuation
TSX:IPCI • CA4581733090
Current stock price
0.08 CAD
-0.01 (-11.11%)
Last:
This IPCI.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. IPCI.CA Profitability Analysis
1.1 Basic Checks
- IPCI had negative earnings in the past year.
- In the past year IPCI had a positive cash flow from operations.
1.2 Ratios
- Looking at the Return On Assets, with a value of -202.69%, IPCI is doing worse than 85.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -202.69% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-182.47%
ROA(5y)-175.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for IPCI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. IPCI.CA Health Analysis
2.1 Basic Checks
- IPCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, IPCI has about the same amount of shares outstanding.
- IPCI has a worse debt/assets ratio than last year.
2.2 Solvency
- IPCI has an Altman-Z score of -111.24. This is a bad value and indicates that IPCI is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of IPCI (-111.24) is worse than 92.68% of its industry peers.
- IPCI has a debt to FCF ratio of 18.06. This is a negative value and a sign of low solvency as IPCI would need 18.06 years to pay back of all of its debts.
- IPCI has a better Debt to FCF ratio (18.06) than 70.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 18.06 | ||
| Altman-Z | -111.24 |
ROIC/WACCN/A
WACC5.78%
2.3 Liquidity
- A Current Ratio of 0.06 indicates that IPCI may have some problems paying its short term obligations.
- IPCI has a Current ratio of 0.06. This is amonst the worse of the industry: IPCI underperforms 95.12% of its industry peers.
- A Quick Ratio of 0.06 indicates that IPCI may have some problems paying its short term obligations.
- IPCI has a worse Quick ratio (0.06) than 95.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.06 | ||
| Quick Ratio | 0.06 |
3. IPCI.CA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 20.14% over the past year.
- IPCI shows a strong growth in Revenue. In the last year, the Revenue has grown by 783.04%.
- Measured over the past years, IPCI shows a very negative growth in Revenue. The Revenue has been decreasing by -58.74% on average per year.
EPS 1Y (TTM)20.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-537.88%
Revenue 1Y (TTM)783.04%
Revenue growth 3Y-73.37%
Revenue growth 5Y-58.74%
Sales Q2Q%260.36%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. IPCI.CA Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IPCI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, IPCI is valued a bit cheaper than the industry average as 73.17% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.19 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. IPCI.CA Dividend Analysis
5.1 Amount
- IPCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IPCI.CA Fundamentals: All Metrics, Ratios and Statistics
TSX:IPCI (3/5/2024, 7:00:00 PM)
0.08
-0.01 (-11.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.80M
Revenue(TTM)904.94K
Net Income(TTM)-3.17M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.29 | ||
| P/FCF | 17.19 | ||
| P/OCF | 17.19 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.13
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY5.82%
OCF(TTM)0
OCFY5.82%
SpS0.03
BVpS-0.5
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -202.69% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 13.31% |
ROA(3y)-182.47%
ROA(5y)-175.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.58
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 18.06 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0% | ||
| Cap/Sales | 0% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.06 | ||
| Quick Ratio | 0.06 | ||
| Altman-Z | -111.24 |
F-Score7
WACC5.78%
ROIC/WACCN/A
Cap/Depr(3y)0%
Cap/Depr(5y)3.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-537.88%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)783.04%
Revenue growth 3Y-73.37%
Revenue growth 5Y-58.74%
Sales Q2Q%260.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y104.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y104.39%
OCF growth 3YN/A
OCF growth 5YN/A
INTELLIPHARMACEUTICS INTERNA / IPCI.CA Fundamental Analysis FAQ
What is the fundamental rating for IPCI stock?
ChartMill assigns a fundamental rating of 1 / 10 to IPCI.CA.
What is the valuation status of INTELLIPHARMACEUTICS INTERNA (IPCI.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to INTELLIPHARMACEUTICS INTERNA (IPCI.CA). This can be considered as Overvalued.
What is the profitability of IPCI stock?
INTELLIPHARMACEUTICS INTERNA (IPCI.CA) has a profitability rating of 0 / 10.